-
Citi Raises PT On PFE To $23
Wednesday, April 13, 2011 - 8:09am | 116Citi has raised its price target on Pfizer (NYSE: PFE) from $20 to $23 and maintains its Hold rating based upon meeting with the company's president and CEO Ian Read to discuss strategy execution. In the report, Citi writes, “We look for Read to 1) divest no-growth/low return/non- core assets, 2)...
-
Jefferies Maintains Buy on Auxilium Pharma (AUXL)
Wednesday, April 13, 2011 - 8:02am | 86Jefferies is out with its report on Auxilium Pharma (NASDAQ: AUXL), maintaining Buy. In a note to clients, Jefferies writes, "Today, AUXL presented an update on Xiaflex sales metrics through March to investors. We continue to believe that Xiaflex adoption in Dupuytren's is gated by reimbursement...
-
BioSante Pharmaceuticals Announces Teva New Drug Application for Bio-T-Gel
Wednesday, April 13, 2011 - 7:56am | 146BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that a New Drug Application has been accepted for filing by the U.S. Food and Drug Administration following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA). The FDA has assigned a PDUFA...
-
Jefferies Maintains Buy on Salix Pharmaceuticals (SLXP)
Wednesday, April 13, 2011 - 7:37am | 87Jefferies is out with its report today on Salix Pharmaceuticals (NASDAQ: SLXP), maintaining Buy. In a note to clients, Jefferies writes, "The success of SLXP hinges on Xifaxan and all signs indicate that usage will continue to go up – despite no formal IBS approval. Our $42 target price is derived...
-
Citigroup Raises PT On Pfizer To $23
Wednesday, April 13, 2011 - 7:33am | 25Citigroup has raised the price target on Pfizer (NYSE: PFE) from $20 to $23 and maintains its Hold rating.
-
Goldman Sachs Upgrades Perrigo to Neutral
Wednesday, April 13, 2011 - 7:05am | 130According to Goldman Sachs, Perrigo (NASDAQ: PRGO) is upgraded to Neutral. Goldman Sachs reported that it upgraded PRGO to Neutral post resolution of issues raised in the FDA warning letter related to its key facility. “Shares have rallied against our Sell rating where we misjudged (1) the...
-
Barclays Opens TEVA With Overweight
Wednesday, April 13, 2011 - 6:07am | 51Analysts at Barclays initiate coverage of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) with an “overweight” rating. The target price for TEVA is set to $32. TEVA shares rose 0.59% to close at $49.27 yesterday. More Analyst Ratings here
-
Top Percentage Gainers And Losers As Of 3:30 p.m. 4/12/2011 (CYH, THC, IDIX, BAC, ANIK, SKH, JPM, UAL, BIOD, SCEI, DGW, CCRT, WMS, EXTR, LFT, SB, HOGS, CAAS, SGI)
Tuesday, April 12, 2011 - 3:48pm | 585Best 1) Community Health Systems (NYSE: CYH): Shares have continued to build on earlier gains, currently up 18.77% to $30.75; sitting near the highs of the day. Skepticism has grown about Tenet Healthcare's (NYSE: THC) lawsuit against the company. The stock took a huge hit in yesterday's session...
-
Top Percentage Gainers And Losers As Of 2 p.m. 4/12/2011 (CYH, THC, IDIX, BAC, SKH, JPM, BIO, REDF, DEER, THC, CYTX, CCRT, WMS, EXTR, LFT, SB, DRRX, BRNC, MCRL)
Tuesday, April 12, 2011 - 2:09pm | 558Best 1) Community Health Systems (NYSE: CYH): Shares are surging 13.09% to $2.32 as skepticism grows about Tenet Healthcare's (NYSE: THC) lawsuit against the company. The stock took a huge hit in yesterday's session, trading down as low as $22.32 after Tenet's lawsuit alleging illegal admission...
-
Perrigo Announces Conclusion of the FDA Re-Inspection
Tuesday, April 12, 2011 - 12:01pm | 68Perrigo (NASDAQ: PRGO) today announced that the Detroit Office of the Food and Drug Administration (FDA) has concluded its re-inspection of Perrigo's Allegan facility. The FDA has informed Perrigo that, effective immediately, the Company has an acceptable regulatory status, such that any pending...
-
Inspire Pharmaceuticals Shareholder Sues Over Merck Deal (MRK, ISPH)
Tuesday, April 12, 2011 - 11:44am | 30Merck's (NYSE: MRK) $430 Million Offer For Inspire Pharma (NASDAQ: ISPH) Is Inadequate, Suit Says.
-
Pfizer Hits 52-Week High (PFE)
Tuesday, April 12, 2011 - 10:34am | 32Pfizer (NYSE: PFE) has hit a 52-week high in today's trading. At last check the year-to-date performance of Pfizer has been a gain of 19.5%.
-
Discovery Laboratories Up Nearly 7% (DSCO)
Tuesday, April 12, 2011 - 10:09am | 94Discovery Laboratories, Inc. (NASDAQ: DSCO) shares are soaring this morning, as the stock has busted through key technical levels. At last check, shares were up 13 cents to $2.02, a gain of 6.7% on nearly 30,000 shares. The $2 level is a key technical level for the stock, and shares could have...
-
Forest Laboratories Announces Successful Completion of Tender Offer for Securities of Clinical Data
Tuesday, April 12, 2011 - 9:29am | 105Forest Laboratories, Inc. (NYSE: FRX) today announced that its indirect wholly-owned subsidiary, Magnolia Acquisition Corp., has accepted for purchase all of the securities validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of, and...
-
Morgan Stanley Maintains 1Q:11E EPS On WCRX
Tuesday, April 12, 2011 - 9:12am | 105Morgan Stanley is maintaining its 1Q11E EPS of $0.84 on shares of Warner Chilcott (NASDAQ: WCRX). “WCRX raised its 2011 EPS guidance following debt refinancing on 3/17,” Morgan Stanley writes. “It also stated in an 8-K on 3/9 that ‘2011 total revenue and cash net income will be relatively lower in...